Efficacy of osimertinib in epidermal growth factor receptor-mutated non-small-cell lung cancer patients with pleural effusion

Efficacy of osimertinib in epidermal growth factor receptor-mutated non-small-cell lung cancer patients with pleural effusion

Abstract Background Osimertinib is a standard first-line treatment for advanced non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations. Although malignant pleural effusion (PE) is a common clinical problem in NSCLC, information about the efficacy of osimertini...

Full description

Bibliographic Details
Main Authors: Hiroshi Nokihara, Hirokazu Ogino, Atsushi Mitsuhashi, Kensuke Kondo, Ei Ogawa, Ryohiko Ozaki, Yohei Yabuki, Hiroto Yoneda, Kenji Otsuka, Yasuhiko Nishioka
Format: Article
Language:English
Published: BMC 2022-06-01
Series:BMC Cancer
Subjects:
Non-small cell lung cancer
Epidermal growth factor receptor
Osimertinib
Pleural effusion
Online Access:https://doi.org/10.1186/s12885-022-09701-2

Similar Items

Similar Items